sPLA2-IIA inhibition as a therapeutic target for FTLD-GRN and neurodegenerative diseases
A novel therapeutic approach targeting sPLA2-IIA, a secreted phospholipase involved in neuroinflammation, for the treatment of frontotemporal lobar degeneration caused by progranulin deficiency (FTLD-GRN) and other neuro...